Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition.

ABSTRACT: Despite novel immunotherapies being approved and established for the treatment of non-small cell lung cancer (NSCLC), ex vivo models predicting individual patients' responses to immunotherapies are missing. Especially immune modulating therapies with moderate response rates urge for biomarkers and/or assays to determine individual prediction of treatment response and investigate resistance mechanisms. Here, we describe a standardized ex vivo tissue culture model to investigate individual tumor responses. NSCLC tissue cultures preserve morphological characteristics of the baseline tumor specimen for up to 12 days ex vivo and also maintain T-cell function for up to 10 days ex vivo. A semi-automated analysis of proliferating and apoptotic tumor cells was used to evaluate tissue responses to t

SUBMITTER: Junk D 

PROVIDER: S-EPMC8464600 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature